Oxaliplatin (L-OHP) treatment of human myeloma cells induces in vitro growth inhibition and apoptotic cell death

European Journal of Cancer

Volumn 38, Issue 8, 2002, Pages 1141-1147

  Tassone, P ^a   Tagliaferri, P ^a   Galea, E ^a   Palmieri, C ^a   Bonelli, P ^b   Martelli, M L ^a   Tuccillo, F ^b   Turco, M C ^c   Venuta, S ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF SALERNO   (Italy)

Author keywords

Apoptosis; Caspase 3; Dexamethasone; IL 6; L OHP; Multiple myeloma; Myeloma cell lines; Oxaliplatin; PARP; Sant7

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CASPASE 3; CISPLATIN; DEXAMETHASONE; INTERLEUKIN 6; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OXALIPLATIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASE 3; CASPASES; CELL DIVISION; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FLOW CYTOMETRY; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; ORGANOPLATINUM COMPOUNDS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR CELLS, CULTURED;

EID: 0036255769     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00017-5     Document Type: Article

References (23)

1. Multiple myeloma: Increasing evidence for a multistep trasformation process
2. Current drug therapy for multiple myeloma
3. Autologous and allogenic transplants of multiple myeloma
4. Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diamino-cyclohexane) platinum (II): New experimental data
5. Experimental study of three platinum platinum complexes: CDDP, CBDCA and L-OHP on L1210 leukemia. Alternate or simultaneous association of two platinum complexes
6. In vitro and in vivo resistance to cisplatin in cell that have lost DNA mismatch repair
7. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel
8. Role of carrier ligand in platinum resistance of human carcinoma cell lines
9. Oxaliplatin: A review of preclinical and clinical studies
10. Synthesis and anti-tumor activities of platinum (II) complexes of 1,2-diaminocyclohexane isomers and their related derivates
11. Comparative effects of a new platinum analog (trans-1-diamine-cyclohexane oxalato-platinum; L'OHP) with CDDP on various cells: Correlation with intracellular accumulation
12. Interleukin-6 in human multiple myeloma
13. Caspases: The executioners of apoptosis
14. Interleukin-6 receptor superantagonists are potent inducers of human multiple myeloma cell death
15. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma
16. Growth inhibition and synergistic induction of apoptosis by Zoledronate and Dexamethasone in human myeloma cell lines
17. Synergistic induction of growth arrest and apoptosis of human myeloma cells by the IL-6 super-antagonist Sant7 and dexamethasone
18. Annexin-V for flow-cytometric detection of phosphatidylserine expression on B-cells undergoing apoptosis
19. Measurement of apoptotic cells in peripheral blood
20. Cleveage of poly-(ADP-ribose) polymerase by a proteinase with properties like ICE
21. Oxaliplatin: Mechanism of action and antineoplastic activity
22. Oxaliplatin effects on DNA integrity and apoptosis induction in human tumor cells
23. Clinical characteristics and reversibility of neurological signs after long term oxaliplatin (L-OHP transplatin) therapy